Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) is a commercial-stage biopharmaceutical company developing and commercializing individualized tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its commercial products are Amtagvi (lifileucel), a one-time TIL therapy for adults with previously treated… From the company’s description.
Over the twelve months to Sep 30, 2026, Iovance Biotherapeutics, Inc. reported revenue of $378.98M, up 51.3% from a year earlier, and a net loss of $220.53M. Its operating margin was −60.8%, and operations used $189.95M in cash. In fiscal 2025, it reported revenue of $263.50M, up 60.6% from fiscal 2024, and a net loss of $390.98M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Iovance Biotherapeutics, Inc. does
In the company’s own words
Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) is a commercial-stage biopharmaceutical company developing and commercializing individualized tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its commercial products are Amtagvi (lifileucel), a one-time TIL therapy for adults with previously treated advanced melanoma, and Proleukin (aldesleukin), an interleukin-2 product used in the Amtagvi treatment regimen and other oncology, manufacturing, clinical and research settings. The company’s pipeline includes TIL therapies being studied in melanoma, non-small cell lung cancer, endometrial cancer and soft tissue sarcomas, as well as next-generation cell therapies. Iovance centrally manufactures commercial Amtagvi and clinical lifileucel at its Iovance Cell Therapy Center in Philadelphia; the facility has potential capacity to supply more than 5,000 patients annually. The company acquired worldwide rights to Proleukin in 2023 and operates its business around TIL product development, manufacturing and commercialization. Its website is www.iovance.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN CARLOS, CA
- Fiscal year end
- December
- CIK
- 1425205
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Iovance Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Iovance Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Iovance Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Iovance Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Iovance Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”